-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As we all know, CAR-T cell therapy can be described as a heavy weapon for blood cancer, but it has not shown great power in the field of solid tumors.
As we all know, CAR-T CAR-T cell therapy can be described as a heavy weapon for blood cancer, but it has not shown great power in the field of solid tumors.
However, CAR-T therapy for solid tumors is achieving breakthroughs step by step.
https://doi.
https://doi.
In solid tumor cancers, most of the proteins responsible for tumor growth and survival are located in the nucleus of the tumor cell, rather than on the cell surface
Neuroblastoma is an aggressive pediatric cancer that is driven by gene expression modifications that promote uncontrolled tumor growth
In this study, the researchers hypothesized that some peptides on the surface of neuroblastoma cells come from proteins that are essential for tumor growth and survival, and can be targeted with synthetic CARs .
Tumor - antigen discovery process and CAR- engineering operation process
Tumor - antigen discovery process and CAR- engineering operation processFirst, the researchers performed the identification of tumor-specific antigens.
First, the researchers performed the identification of tumor-specific antigens.
After identifying the targetable antigen PHOX2B , the researchers began to develop PC-CAR , and tested and tested its efficacy
PHOX2B- specific PC-CAR T cells induce effective tumor killing in vitro and in vivo and break conventional HLA limitations
PHOX2B- specific PC-CAR T cells induce effective tumor killing in vitro and in vivo and break conventional HLA limitationsSubsequently, the research team tested the PC-CAR therapy in mice , and the results showed that the therapy induced a large amount of up-regulation of MHC in tumors .
Subsequently, the research team tested the PC-CAR therapy in mice , and the results showed that the therapy induced a large amount of up-regulation of MHC in tumors .
The researchers said: " We are excited about this research because it allows us to track the past can now be considered as ' not medicine ' is an important driver of cancer
[1] https://#Abs1
https://#Abs1[2]https://